Resplice

Hyderabad, India Founded: 2022 • Age: 4 yrs
Conducts clinical trials for autism using microbiota transfer therapy.

About Resplice

Resplice is a Healthcare company based in Hyderabad (India) founded in 2022. Conducts clinical trials for autism using microbiota transfer therapy. It operates on a B2B model. The company has 1 employees. Its Indian entity Providence Microbiome Research Center Private Limited reported revenue of β‚Ή4.3 Lakh. Resplice offers products and services including Gut Symbiont Restoration Therapy. Its focus areas include Health, Medical Research, Clinical Trials and Microbiome Studies.

Company details

GSRT focuses on developing gut symbiont restoration therapy to treat autism spectrum disorders through faecal microbiota transfer. Based in Hyderabad, India, they run academic clinical trials at St. Theresa Hospital, assessing gut microbiome and epigenetic changes. Collaborations with institutions like CDFD support studies on autisms causes and potential prevention. The initiative aims to explore gene-environment interactions and improve therapeutic outcomes.

Key Metrics
  • Annual Revenue
    ₹4.3 Lakh

    FY 2024 · +194% YoY

  • Net Loss
    -₹5.8 Lakh

    FY 2024 · -135% margin

  • EBITDA
    -₹5.8 Lakh

    FY 2024 · -135% margin

  • Employee Count
    1

Products & Services of Resplice

Resplice offers a comprehensive portfolio of products and services, including Gut Symbiont Restoration Therapy.

Gut Symbiont Restoration Therapy
Medical Treatment

Uses faecal microbiota transfer to address autism symptoms

Board of directors of Providence Microbiome Research Center Private Limited (Resplice)

Providence Microbiome Research Center Private Limited is the primary company behind Resplice. The board of Providence Microbiome Research Center Private Limited currently have 2 directors; the longest-serving is Chandrashekhar Thodupunuri, appointed in 2020.

DirectorDesignationAppointedTenureEntity
Chandrashekhar Thodupunuri
DIN 08873815
Director11 Sep 20206 yrs 2 moProvidence Microbiome Research Center Private Limited
Keerthi Sarabu
DIN 08873816
Director11 Sep 20206 yrs 2 moProvidence Microbiome Research Center Private Limited

Financials of Resplice

Figures of Providence Microbiome Research Center Private Limited, the primary company behind Resplice, for FY 2024. Revenue was ₹4.3 Lakh (+194% year on year). Net loss was -₹5.8 Lakh (-135% margin). EBITDA was -₹5.8 Lakh (-135% margin).

  • ₹4.3 LakhRevenue · FY 2024 · +194% YoY
  • -₹5.8 LakhNet loss · -135% margin
  • -₹5.8 LakhEBITDA · -135% margin
  • ₹1 LakhPaid-up capital

Balance sheet, profit and loss, cash flow and ratios of Providence Microbiome Research Center Private Limited are on its company page.

Premium access

Detailed financial statements for Resplice

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Resplice

Resplice was founded in 2022.

Resplice is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Resplice has 1 employees.

The primary company behind Resplice, Providence Microbiome Research Center Private Limited, reported revenue of β‚Ή4.3 Lakh for FY 2024, up 194% year on year.

GSRT focuses on developing gut symbiont restoration therapy to treat autism spectrum disorders through faecal microbiota transfer. Based in Hyderabad, India, they run academic clinical trials at St. Theresa Hospital, assessing gut microbiome and epigenetic changes. Collaborations with institutions like CDFD support studies on autisms causes and potential prevention. The initiative aims to explore gene-environment interactions and improve therapeutic outcomes.

Resplice offers Gut Symbiont Restoration Therapy.

Resplice operates through Providence Microbiome Research Center Private Limited.

The legal entities of Resplice currently have 2 directors, including Chandrashekhar Thodupunuri, Keerthi Sarabu.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available